Esperion Therapeutics Inc (ESPR)vsViatris Inc (VTRS)
ESPR
Esperion Therapeutics Inc
$2.76
+5.34%
HEALTHCARE · Cap: $654.87M
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 3447% more annual revenue ($14.30B vs $403.13M). ESPR leads profitability with a -5.6% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
ESPR
Hold44
out of 100
Grade: D
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 50.6%
Revenue surging 143.7% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.6% — below average capital efficiency
Currently unprofitable
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ESPR
The strongest argument for ESPR centers on Operating Margin, Revenue Growth. Revenue growth of 143.7% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : ESPR
The primary concerns for ESPR are EPS Growth, Market Cap, Return on Equity.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ESPR profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
ESPR carries more volatility with a beta of 1.11 — expect wider price swings.
ESPR is growing revenue faster at 143.7% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (50/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Esperion Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?